CLINICAL TRIAL: A PHASE II TRIAL OF VACCINATION WITH PEPTIDES FOR PATIENTS WITH

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项针对可测量的IV期黑色素瘤患者的随机、多中心研究。 这项研究将：（a）估计向I类MHC限制性肽中添加辅助肽是否增强了T细胞对I类MHC限制性肽的应答，（B）表征疫苗诱导的CD 8 + T细胞的表型，（c）测定辅助T细胞对每种辅助肽的应答，（d）获得关于每三个月加强接种是否可以维持对肽疫苗的免疫应答的初步数据，和（e）获得关于对12-表位肽疫苗的细胞免疫应答是否与临床结果相关的初步数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, multicenter study for patients with measurable, stage IV melanoma. This study will: (a) estimate whether the addition of helper peptides to class I MHC-restricted peptides augments T-cell responses to the Class I MHC-restricted peptides, (b) characterize the phenotype of vaccine-induced CD8+ T cells, (c) determine the helper T-cell response to each helper peptide, (d) obtain preliminary data on whether booster vaccination every three months may maintain immune responses to a peptide vaccine, and (e) obtain preliminary data on whether cellular immune responses to a 12-epitope peptide vaccine correlates with clinical outcome.